Percheron Therapeutics Limited has released a press release.
First approval for ATL1102 Phase IIb DMD clinical trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Limb Girdle Muscular Dystrophy R2 animal study commenced
- Positive outcomes in DMD combination therapy animal study
- Antisense Therapeutics CEO announces retirement
- ATL1102 tox study to support clinical program in the US
- Dosing commenced in DMD combination therapy study
Later from Percheron Therapeutics
- Receipt of R&D Tax Incentive Payment
- Dosing commenced in the ATL1102 toxicology study
- PIIb DMD trial approved in Bulgaria- UK, Australia advancing
- Chief Executive Officer and Managing Director Appointment
- First Patient Dosed in ATL1102 Phase IIb DMD Trial
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics